Anthony
TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)
New Era in Biologically-targeted Radiation Therapy for Cancer Treatment
Developing targeted drugs for boron neutron capture therapy to treat refractory cancers
TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.
Developing targeted drugs for boron neutron capture therapy to treat refractory cancers
VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy
TAE Life Sciences and CNAO (National Center of Oncological Hadrontherapy) Announce a Research and Clinical Collaboration for the Implementation of a New Facility with Boron Neutron Capture Therapy System in Italy
TAE Life Sciences to Present at Solebury Trout Summer 2020 Private Company Showcase
Have questions about BNCT? Get answers on our new BNCT Forum